Targeting the nucleotide excision repair pathway for therapeutic applications

N. S. Gavande, P. S. VanderVere-Carozza, K. S. Pawelczak, John Turchi

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

The NER (nucleotide excisions repair) pathway involves a coordinated series of interactions that enable the recognition and repair of bulky adduct DNA damage. Our understanding of the NER pathway has been significantly enhanced by the identification, characterization, and molecular analysis of cells and tissue obtained from individuals with Xeroderma pigmentosum. Reconstitution of the pathway in vitro has also enabled the molecular interactions to be interrogated in great detail. Finally, high-resolution structural analysis of many of the components provides a molecular basis for many of the interactions. Together, this convergence of knowledge provides a framework for efforts to disrupt the NER pathway to aid in the treatment of human disease, most notably cancer. It has been suggested all cancers display some defect in DNA repair and it has been demonstrated that the ability of cancer cells to repair therapeutically induced DNA damage impacts therapeutic efficacy. Although initial studies involving agents speculated to inhibit NER languished and were plagued by lack of specificity and a defined mechanism of action, more recent approaches to exploit synthetic lethal interactions and develop high-affinity chemical inhibitors have proven considerably more effective. In this chapter, we will highlight recent advances and discuss previous failures in targeting NER to pave the way for future DNA repair targeted agents and their use in cancer therapy.

Original languageEnglish (US)
Title of host publicationDNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition
PublisherElsevier Inc.
Pages135-150
Number of pages16
ISBN (Print)9780128035825
DOIs
StatePublished - Jun 21 2016

Fingerprint

DNA Repair
Therapeutics
DNA Damage
Neoplasms
Xeroderma Pigmentosum

Keywords

  • Chemical biology
  • Cisplatin
  • DNA damage
  • Inhibitors
  • Nucleotide excision repair
  • Replication protein A
  • Xeroderma pigmentosum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gavande, N. S., VanderVere-Carozza, P. S., Pawelczak, K. S., & Turchi, J. (2016). Targeting the nucleotide excision repair pathway for therapeutic applications. In DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition (pp. 135-150). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-803582-5.00005-X

Targeting the nucleotide excision repair pathway for therapeutic applications. / Gavande, N. S.; VanderVere-Carozza, P. S.; Pawelczak, K. S.; Turchi, John.

DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition. Elsevier Inc., 2016. p. 135-150.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gavande, NS, VanderVere-Carozza, PS, Pawelczak, KS & Turchi, J 2016, Targeting the nucleotide excision repair pathway for therapeutic applications. in DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition. Elsevier Inc., pp. 135-150. https://doi.org/10.1016/B978-0-12-803582-5.00005-X
Gavande NS, VanderVere-Carozza PS, Pawelczak KS, Turchi J. Targeting the nucleotide excision repair pathway for therapeutic applications. In DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition. Elsevier Inc. 2016. p. 135-150 https://doi.org/10.1016/B978-0-12-803582-5.00005-X
Gavande, N. S. ; VanderVere-Carozza, P. S. ; Pawelczak, K. S. ; Turchi, John. / Targeting the nucleotide excision repair pathway for therapeutic applications. DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition. Elsevier Inc., 2016. pp. 135-150
@inbook{536e87b0331e40ea8a416d63b9845c8a,
title = "Targeting the nucleotide excision repair pathway for therapeutic applications",
abstract = "The NER (nucleotide excisions repair) pathway involves a coordinated series of interactions that enable the recognition and repair of bulky adduct DNA damage. Our understanding of the NER pathway has been significantly enhanced by the identification, characterization, and molecular analysis of cells and tissue obtained from individuals with Xeroderma pigmentosum. Reconstitution of the pathway in vitro has also enabled the molecular interactions to be interrogated in great detail. Finally, high-resolution structural analysis of many of the components provides a molecular basis for many of the interactions. Together, this convergence of knowledge provides a framework for efforts to disrupt the NER pathway to aid in the treatment of human disease, most notably cancer. It has been suggested all cancers display some defect in DNA repair and it has been demonstrated that the ability of cancer cells to repair therapeutically induced DNA damage impacts therapeutic efficacy. Although initial studies involving agents speculated to inhibit NER languished and were plagued by lack of specificity and a defined mechanism of action, more recent approaches to exploit synthetic lethal interactions and develop high-affinity chemical inhibitors have proven considerably more effective. In this chapter, we will highlight recent advances and discuss previous failures in targeting NER to pave the way for future DNA repair targeted agents and their use in cancer therapy.",
keywords = "Chemical biology, Cisplatin, DNA damage, Inhibitors, Nucleotide excision repair, Replication protein A, Xeroderma pigmentosum",
author = "Gavande, {N. S.} and VanderVere-Carozza, {P. S.} and Pawelczak, {K. S.} and John Turchi",
year = "2016",
month = "6",
day = "21",
doi = "10.1016/B978-0-12-803582-5.00005-X",
language = "English (US)",
isbn = "9780128035825",
pages = "135--150",
booktitle = "DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Targeting the nucleotide excision repair pathway for therapeutic applications

AU - Gavande, N. S.

AU - VanderVere-Carozza, P. S.

AU - Pawelczak, K. S.

AU - Turchi, John

PY - 2016/6/21

Y1 - 2016/6/21

N2 - The NER (nucleotide excisions repair) pathway involves a coordinated series of interactions that enable the recognition and repair of bulky adduct DNA damage. Our understanding of the NER pathway has been significantly enhanced by the identification, characterization, and molecular analysis of cells and tissue obtained from individuals with Xeroderma pigmentosum. Reconstitution of the pathway in vitro has also enabled the molecular interactions to be interrogated in great detail. Finally, high-resolution structural analysis of many of the components provides a molecular basis for many of the interactions. Together, this convergence of knowledge provides a framework for efforts to disrupt the NER pathway to aid in the treatment of human disease, most notably cancer. It has been suggested all cancers display some defect in DNA repair and it has been demonstrated that the ability of cancer cells to repair therapeutically induced DNA damage impacts therapeutic efficacy. Although initial studies involving agents speculated to inhibit NER languished and were plagued by lack of specificity and a defined mechanism of action, more recent approaches to exploit synthetic lethal interactions and develop high-affinity chemical inhibitors have proven considerably more effective. In this chapter, we will highlight recent advances and discuss previous failures in targeting NER to pave the way for future DNA repair targeted agents and their use in cancer therapy.

AB - The NER (nucleotide excisions repair) pathway involves a coordinated series of interactions that enable the recognition and repair of bulky adduct DNA damage. Our understanding of the NER pathway has been significantly enhanced by the identification, characterization, and molecular analysis of cells and tissue obtained from individuals with Xeroderma pigmentosum. Reconstitution of the pathway in vitro has also enabled the molecular interactions to be interrogated in great detail. Finally, high-resolution structural analysis of many of the components provides a molecular basis for many of the interactions. Together, this convergence of knowledge provides a framework for efforts to disrupt the NER pathway to aid in the treatment of human disease, most notably cancer. It has been suggested all cancers display some defect in DNA repair and it has been demonstrated that the ability of cancer cells to repair therapeutically induced DNA damage impacts therapeutic efficacy. Although initial studies involving agents speculated to inhibit NER languished and were plagued by lack of specificity and a defined mechanism of action, more recent approaches to exploit synthetic lethal interactions and develop high-affinity chemical inhibitors have proven considerably more effective. In this chapter, we will highlight recent advances and discuss previous failures in targeting NER to pave the way for future DNA repair targeted agents and their use in cancer therapy.

KW - Chemical biology

KW - Cisplatin

KW - DNA damage

KW - Inhibitors

KW - Nucleotide excision repair

KW - Replication protein A

KW - Xeroderma pigmentosum

UR - http://www.scopus.com/inward/record.url?scp=84987888637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987888637&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-803582-5.00005-X

DO - 10.1016/B978-0-12-803582-5.00005-X

M3 - Chapter

AN - SCOPUS:84987888637

SN - 9780128035825

SP - 135

EP - 150

BT - DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition

PB - Elsevier Inc.

ER -